DE69527542D1 - Pulverformulierungen die melizitose als verdünnungsmittel enthalten - Google Patents

Pulverformulierungen die melizitose als verdünnungsmittel enthalten

Info

Publication number
DE69527542D1
DE69527542D1 DE69527542T DE69527542T DE69527542D1 DE 69527542 D1 DE69527542 D1 DE 69527542D1 DE 69527542 T DE69527542 T DE 69527542T DE 69527542 T DE69527542 T DE 69527542T DE 69527542 D1 DE69527542 D1 DE 69527542D1
Authority
DE
Germany
Prior art keywords
melicitosis
thinner
formulations containing
powder formulations
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527542T
Other languages
English (en)
Other versions
DE69527542T2 (de
Inventor
Kjell Baeckstroem
Ann Johansson
Helena Linden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69527542D1 publication Critical patent/DE69527542D1/de
Publication of DE69527542T2 publication Critical patent/DE69527542T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
DE69527542T 1994-12-22 1995-12-19 Pulverformulierungen die melizitose als verdünnungsmittel enthalten Expired - Fee Related DE69527542T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations
PCT/SE1995/001541 WO1996019207A1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent

Publications (2)

Publication Number Publication Date
DE69527542D1 true DE69527542D1 (de) 2002-08-29
DE69527542T2 DE69527542T2 (de) 2003-01-30

Family

ID=20396435

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69527542T Expired - Fee Related DE69527542T2 (de) 1994-12-22 1995-12-19 Pulverformulierungen die melizitose als verdünnungsmittel enthalten
DE69533294T Expired - Fee Related DE69533294T2 (de) 1994-12-22 1995-12-19 Pulverformulierungen, die Melezitose als Verdünnungsmittel enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69533294T Expired - Fee Related DE69533294T2 (de) 1994-12-22 1995-12-19 Pulverformulierungen, die Melezitose als Verdünnungsmittel enthalten

Country Status (34)

Country Link
US (1) US6004574A (de)
EP (2) EP0799030B1 (de)
JP (1) JPH10510828A (de)
KR (1) KR100391873B1 (de)
CN (1) CN1080114C (de)
AR (1) AR002261A1 (de)
AT (2) ATE271382T1 (de)
AU (1) AU702898B2 (de)
BR (1) BR9510422A (de)
CA (1) CA2206803A1 (de)
CZ (1) CZ288487B6 (de)
DE (2) DE69527542T2 (de)
DK (2) DK0799030T3 (de)
EE (1) EE03381B1 (de)
ES (2) ES2177674T3 (de)
FI (1) FI972654A (de)
HK (1) HK1003619A1 (de)
HU (1) HU217975B (de)
IL (1) IL116459A (de)
IS (1) IS1848B (de)
MY (1) MY114211A (de)
NO (1) NO315966B1 (de)
NZ (1) NZ298168A (de)
PL (1) PL183944B1 (de)
PT (2) PT1224929E (de)
RU (1) RU2144819C1 (de)
SA (1) SA95160484B1 (de)
SE (1) SE9404468D0 (de)
SK (1) SK283147B6 (de)
TR (1) TR199501632A1 (de)
TW (1) TW474823B (de)
UA (1) UA44757C2 (de)
WO (1) WO1996019207A1 (de)
ZA (1) ZA9510753B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
MX9704550A (es) * 1994-12-22 1997-10-31 Astra Ab Formulaciones de medicamentos en aerosol.
DE69806362T2 (de) * 1997-03-20 2003-01-30 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
TWI277425B (en) * 1999-04-13 2007-04-01 Lilly Co Eli Pulmonary administration of dry powder formulations for treating infertility
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
EP1309312A2 (de) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
BR0214279A (pt) 2001-11-19 2005-12-20 Becton Dickinson Co Composições farmacêuticas em forma particulada
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1789075A4 (de) * 2004-08-25 2009-07-01 Uab Research Foundation Absorptionsverbesserer für die arzneimittelverabreichung
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CN101618023B (zh) * 2008-06-30 2011-11-30 江苏先声药物研究有限公司 一种制备微粉化蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CA2796729C (en) 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
US9480966B2 (en) * 2012-04-30 2016-11-01 General Electric Company Substrates and methods for collection, stabilization and elution of biomolecules
EP3124028B1 (de) * 2014-03-25 2019-06-26 National University Corporation Kagawa University Mittel zur prävention von malariaübertragung mit seltenem zucker als wirkstoff und mittel zur regulierung des wachstums von malariaparasiten
JP2017524379A (ja) * 2014-06-30 2017-08-31 テイト アンド ライル イングレディエンツ アメリカス リミテッド ライアビリティ カンパニーＴａｔｅ ＆ Ｌｙｌｅ Ｉｎｇｒｅｄｉｅｎｔｓ Ａｍｅｒｉｃａｓ Ｌｌｃ 消耗品用コーティング組成物
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
ES2912965T3 (es) 2015-09-09 2022-05-30 Drawbridge Health Inc Dispositivos para la recopilación, estabilización y conservación de muestras
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (de) * 1957-01-31 1957-04-11
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE3326089A1 (de) * 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
EP0360340A1 (de) * 1988-09-19 1990-03-28 Akzo N.V. Peptidenthaltende Zubereitung zur intranasalen Verabreichung
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
EP0621774B1 (de) * 1992-01-21 1996-12-18 Sri International Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
BR9307141A (pt) * 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation

Also Published As

Publication number Publication date
ES2222306T3 (es) 2005-02-01
CN1171049A (zh) 1998-01-21
ZA9510753B (en) 1996-06-24
JPH10510828A (ja) 1998-10-20
AU702898B2 (en) 1999-03-11
DK0799030T3 (da) 2002-09-16
CN1080114C (zh) 2002-03-06
HU217975B (hu) 2000-05-28
EP1224929A2 (de) 2002-07-24
CZ194697A3 (en) 1997-10-15
DE69527542T2 (de) 2003-01-30
WO1996019207A1 (en) 1996-06-27
NO972660D0 (no) 1997-06-10
NZ298168A (en) 1999-08-30
HK1003619A1 (en) 1998-11-06
SA95160484B1 (ar) 2005-10-01
EP1224929A3 (de) 2002-12-18
ATE220900T1 (de) 2002-08-15
IS1848B (is) 2003-02-07
IS4495A (is) 1997-06-03
DE69533294D1 (de) 2004-08-26
HUT77648A (hu) 1998-07-28
FI972654A0 (fi) 1997-06-19
PL183944B1 (pl) 2002-08-30
SK283147B6 (sk) 2003-03-04
TR199501632A1 (tr) 1997-03-21
CA2206803A1 (en) 1996-06-27
ATE271382T1 (de) 2004-08-15
SK81297A3 (en) 1997-11-05
EP0799030B1 (de) 2002-07-24
RU2144819C1 (ru) 2000-01-27
NO972660L (no) 1997-06-10
UA44757C2 (uk) 2002-03-15
PT1224929E (pt) 2004-10-29
AR002261A1 (es) 1998-03-11
IL116459A (en) 2002-11-10
CZ288487B6 (en) 2001-06-13
KR100391873B1 (ko) 2003-10-17
ES2177674T3 (es) 2002-12-16
EP0799030A1 (de) 1997-10-08
TW474823B (en) 2002-02-01
NO315966B1 (no) 2003-11-24
AU4359296A (en) 1996-07-10
PT799030E (pt) 2002-11-29
EE9700135A (et) 1997-12-15
PL320751A1 (en) 1997-10-27
DK1224929T3 (da) 2004-10-04
EP1224929B1 (de) 2004-07-21
BR9510422A (pt) 1998-07-07
US6004574A (en) 1999-12-21
SE9404468D0 (sv) 1994-12-22
IL116459A0 (en) 1996-03-31
EE03381B1 (et) 2001-04-16
MY114211A (en) 2002-08-30
MX9704551A (es) 1997-10-31
DE69533294T2 (de) 2005-05-19
FI972654A (fi) 1997-06-19

Similar Documents

Publication Publication Date Title
DE69527542T2 (de) Pulverformulierungen die melizitose als verdünnungsmittel enthalten
PL309563A1 (en) Solid composition for hair care containing a special structuring ingredient
FI952671A0 (fi) Puristustyökalu
ZA912033B (en) Deodorising cosmetic agents
ZA954560B (en) Thickened cosmetic compositions
DE69606543T2 (de) Formulierungen die als tenside verzweigte alkoholethersulfate enthalten
DE69600018T2 (de) Kosmetische Lichtschutzmittel, die Amidverbindungen enthalten
ZA973147B (en) Skin care compositions containing melinamide and a retinoid
DE69400752D1 (de) Zusammensetzungen die hexafluorpropan enthalten
DE69408148D1 (de) Reinigungszusammensetzungen die hydroxyalkanoatderivate enthalten
AU2094901A (en) Compositions containing a retinoid and a stilbene for skin care
GB2316003B (en) Hair care compositions
ATE258011T1 (de) Benetzbare pulverformulierungen
AU119364S (en) Cosmetic organizer
GB9124540D0 (en) Oily cosmetic composition
GB2300644B (en) Whitening agent formulations
AU118813S (en) Cosmetic compact
DE59508616D1 (de) Indan als Riechstoff
KR950029813U (ko) 프레스의 슬라이드
KR950026876U (ko) 홈가공용 다이
KR960019802U (ko) 콤팩트 화장 용기 조립체
KR970027535U (ko) 다이 분할식 분말 성형 장치
KR960009793U (ko) 소도구 일체형 화장용구
KR960009792U (ko) 소도구 일체형 화장용구
KR960009794U (ko) 소도구 일체형 화장용구

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee